Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that decreases stomach acid production.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Reduction of risk of NSAID-induced gastric ulcers in patients taking chronic NSAIDs.
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally once daily for 4 to 8 weeks. For maintenance of healing, 40 mg orally once daily may be continued.
* **GERD (symptomatic relief):** 20 mg to 40 mg orally once daily.
* **NSAID-induced gastric ulcers:** 40 mg orally once daily.
* **Zollinger-Ellison syndrome:** 40 mg orally twice daily, may be increased to a maximum of 80 mg twice daily.
## Pediatric Dosing
* **Erosive esophagitis (12 years and older):** 40 mg orally once daily for 4 to 8 weeks.
* **GERD (5 years and older):** 20 mg to 40 mg orally once daily.
* **Note:** Dosing for younger pediatric patients is not well-established and should be guided by specialist recommendation and available literature.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose is 20 mg orally once daily for severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is generally required.
## Contraindications
* Known hypersensitivity to pantoprazole or any of its components.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Less Common/Serious:
* **Long-term use:** Increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia.
* **Acute Interstitial Nephritis (AIN):** Can occur at any time during therapy.
* **Fundic Gland Polyps:** Benign, associated with long-term use.
## Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, vitamin B12. May decrease absorption.
* **Methotrexate:** May increase levels of methotrexate.
* **CYP2C19 substrates:** Clopidogrel (pantoprazole may decrease its antiplatelet effect, though clinical significance is debated).
* **CYP3A4 inducers/inhibitors:** Potential for altered metabolism of other drugs.
## Monitoring
* Magnesium levels, particularly with prolonged use (typically > 3 months, often > 1 year).
* Bone mineral density may be considered in patients at risk for osteoporosis, especially with prolonged therapy.
* Monitor for signs and symptoms of *C. difficile* infection.
## Clinical Pearls
* Administer 30 minutes to 1 hour before a meal.
* For patients who cannot swallow whole tablets, pantoprazole for delayed-release oral suspension is available.
* While generally well-tolerated, be mindful of potential long-term sequelae with chronic use.
***
*Disclaimer: This information is intended for clinical use and does not substitute for professional judgment. Always consult the most current prescribing information and institutional protocols for definitive guidance.*
